NCT06757907

Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Al-Azhar University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

Conditions

• Herpetic Keratitis

Interventions

Type	Name	Description
DRUG	Acyclovir 400 MG	Acyclovir is used to treat infections caused by certain types of viruses.
DRUG	Ganciclovir (GCV)	Ganciclovir is an anti-viral drug

Timeline

• Start date: 2024-10-01
• Primary completion: 2024-12-20
• Completion: 2024-12-25
• First posted: 2025-01-03
• Last updated: 2025-01-03

Locations

1 site across 1 country: Egypt